Are you over 18 and want to see adult content?
More Annotations
Siddeshwara Travels: Book Luxury Bus, Van & Car Rentals in Bangalore
Are you over 18 and want to see adult content?
PENTA - Výrobce a dodavatel čistých, laboratorních, speciálních, farmaceutických a technických chemikálií
Are you over 18 and want to see adult content?
Anschreiben für Bewerbung als PDF & Druckvorlage
Are you over 18 and want to see adult content?
A complete backup of benefits-ginger.com
Are you over 18 and want to see adult content?
Autopflege, Lackpflege & Waschanlagenprodukte von SONAX - reinigen und polieren wie die Profis
Are you over 18 and want to see adult content?
www.OVERKILL.pl - Oficjalna strona fan klubu zespołu Metallica - Strona główna
Are you over 18 and want to see adult content?
Favourite Annotations
ՀԱՅ ՄԵԴԻԱ - Հետաքրքիր և ժամանցային տեղեկատվական հարթակ
Are you over 18 and want to see adult content?
电子工程专辑 EE Times China -提供有关电子工程及电子设计的最新资讯和科技趋势
Are you over 18 and want to see adult content?
เครื่องคิดเลข – คิดเลข เครื่องคิดเลข วิธีคิดเลขง่าย ๆ การคิดเลข วิธีคิดเลข
Are you over 18 and want to see adult content?
Météo Geneve - 1er site météo pour Genève et sa région - previsions gratuites à 15 jours
Are you over 18 and want to see adult content?
Снять квартиру без посредников в Москве - аренда квартир без комиссии - Rentor
Are you over 18 and want to see adult content?
Home | Work Boots & Shoes: Royer, Timberland, Blundston, Canada West
Are you over 18 and want to see adult content?
torcache.com - This website is for sale! - torcache Resources and Information.
Are you over 18 and want to see adult content?
MOBOPINIONS – Gathering market research insight from mobile app users
Are you over 18 and want to see adult content?
Loophunter: Download royalty free loops and samples, Acid loops, Apple loops, Midi and Rex2
Are you over 18 and want to see adult content?
Panamafolkdress – Pollera Panameña
Are you over 18 and want to see adult content?
onecreativemommy.com - where design, imagination and learning come together
Are you over 18 and want to see adult content?
Text
region.
BREAKING BARRIERS: WOMEN IN ONCOLOGY, LEARNING FROM Philadelphia, where Fox Chase is located, has long been a center for scientific and medical education and research. The first medical school in the United States opened in 1765 at the College of Philadelphia and eventually evolved into the University of Pennsylvania’s Perelman School of Medicine. BIDEN REQUESTS $6.5B TO FUND CANCER-FOCUSED ARPA-H, AN Nathaniel Berlin, an experimental hematologist, joined NCI in 1956 as head of the Metabolism Service in the General Medicine Branch and held that position until 1966, when he became chief of NCI’s Metabolism Branch, a position he held until 1971. ISSUE 18 - THE CANCER LETTER By Phoenix A. Matthews and Robert A. Winn. Mainstream tobacco control advocates are celebrating the recent announcement that the Food and Drug Administration is poised to restrict the manufacture and sale of mentholated cigarettes and cigars. Free Guest Editorial. JANSSEN SUBMITS MARKETING AUTHORIZATION The Janssen Pharmaceutical Companies of Johnson & Johnson has submitted a Marketing Authorization Application to the European Medicines Agency seeking approval of cilta-cel, an investigational B cell maturation antigen (BCMA)-directed chimeric antigen receptor T cell (CAR T) therapy, for the treatment of patients with relapsed and/or refractory multiple myeloma. The HOME - THE CANCER LETTEROHIO STATE EXPANDS ASSISTANCE PROGRAM TO GIVE OUT PREVIOUSLY DISPENSED CANCER DRUGSCALENDAR May 14, 2021. May 07, 2021. Apr 30, 2021. View More. The Cancer Letter is an independent weekly news publication and the leading source for information on the issues that shape oncology. SENATE LEADERS SHOW BIPARTISAN SUPPORT FOR BIDEN’S FY22 President Joe Biden is requesting $52 billion in FY2022 for NIH—$9 billion above the enacted FY21 level—of which $6.5 billion is slated for the proposed Advanced Research Projects Agency for Health. While the $9 billion investment, if approved by Congress, would amount to the largest raise in the history of NIH, $2.5 billion of that “1001CUTS”—A GYN ONCOLOGIST EXAMINES THE TOLL OF SEXISM IN The documentary is being completed, and the trailer is available here.The goal is for the film to be released in early 2022. Temkin is raising funds for the production costs here. “When I thought about it, telling a story about the OR made the most sense, and the stories of women and their personal experiences as surgeons in the operating room seemed like the highest impact place to tell the DONALD PINKEL: THE CANCER PIONEER WHO “INTRODUCED THE WORD In collaboration with Donald Pinkel’s daughter, Mary Pinkel, the Cancer History Project is preserving and republishing materials from his personal archive. The documents include acceptance remarks, personal letters, editorials, photographs, video archives, and celebrations of his life’s work. The archive’s index, as well as a conversation between Pinkel and his daughter, appear below ST. JUDE’S $11.5B, SIX-YEAR PLAN AIMS TO IMPROVE GLOBAL Small dreams have no power to move hearts, and in a new six-year strategic plan, St. Jude Children’s Research Hospital is thinking very big. What would it take to drastically increase cure rates for childhood cancer worldwide? St. Jude’s answer: $11.5 billion and an additional 1,400 jobs. To get a rough sense of scale, work CTCA LEAVES TULSA AND PHILADELPHIA; TULSA MOVE COMES AMID “CTCA will continue investing in key markets that will build on more than 30 years of patient-centered, high-quality care.” Philadelphia is a tough market, where CTCA had to compete with three NCI-designated institutions—two of them Comprehensive Cancer Centers—located in the city limits as well as multiple high-quality health systems in theregion.
BREAKING BARRIERS: WOMEN IN ONCOLOGY, LEARNING FROM Philadelphia, where Fox Chase is located, has long been a center for scientific and medical education and research. The first medical school in the United States opened in 1765 at the College of Philadelphia and eventually evolved into the University of Pennsylvania’s Perelman School of Medicine. BIDEN REQUESTS $6.5B TO FUND CANCER-FOCUSED ARPA-H, AN Nathaniel Berlin, an experimental hematologist, joined NCI in 1956 as head of the Metabolism Service in the General Medicine Branch and held that position until 1966, when he became chief of NCI’s Metabolism Branch, a position he held until 1971. ISSUE 18 - THE CANCER LETTER By Phoenix A. Matthews and Robert A. Winn. Mainstream tobacco control advocates are celebrating the recent announcement that the Food and Drug Administration is poised to restrict the manufacture and sale of mentholated cigarettes and cigars. Free Guest Editorial. JANSSEN SUBMITS MARKETING AUTHORIZATION The Janssen Pharmaceutical Companies of Johnson & Johnson has submitted a Marketing Authorization Application to the European Medicines Agency seeking approval of cilta-cel, an investigational B cell maturation antigen (BCMA)-directed chimeric antigen receptor T cell (CAR T) therapy, for the treatment of patients with relapsed and/or refractory multiple myeloma. TheTHE CANCER LETTER
All issues of The Cancer Letter, from inception in 1973 through the present, are available in our digital archives. SEARCH. SUBSCRIBE - THE CANCER LETTER The Cancer Letter offers a variety of subscriber packages for individuals, groups, and institutions of all sizes. Subscriptions include digital access to all 46 annual issues of The Cancer Letter, special reports, and access to full newsletter archives dating back to1973.
NCI TRIALS FOR MAY 2021 The National Cancer Institute approved the following clinical research studies last month. For further information, contact the principal investigator listed. Phase I – PED-CITN-03 Phase 1 Trial of Hu5F9-G4 (Magrolimab) Combined with Dinutuximab in Children and Young Adults with Relapsed and Refractory Neuroblastoma or Relapsed Osteosarcoma Cancer Immunotherapy Trials Network Majzner, AMERICAN RED CROSS AND AMERICAN CANCER SOCIETY COLLABORATE The American Red Cross and the American Cancer Society are collaborating to encourage people to donate blood for cancer treatment. According to the American Cancer Society, many patient visits and procedures were forced to delay or cancel early in the pandemic to reduce the risk of exposure to COVID-19. With procedures resuming, blood donations are PRECISION ONCOLOGY MUST EVOLVE TO ADDRESS HEALTH Every person facing a cancer diagnosis deserves access to the best possible tests and treatments for their disease. It’s really that simple. Even better—it’s entirely feasible. Biomarker-based cancer therapies are the cornerstone of precision oncology and hold promise for expanding access to the most effective treatment options for every patient. With genomic profiling, we can FDA LAUNCHES CROWDSOURCING CHALLENGE TO SOLICIT INPUT ON FDA’s Oncology Center of Excellence launched the “Send Your Oncology Research Questions to FDA” crowdsourcing challenge. OCE is using this challenge to provide an opportunity for interested stakeholders to submit ideas for research using pooled analyses of oncologic clinical trial data directly to FDA’s scientific staff. ISSUE 18 - THE CANCER LETTER By Phoenix A. Matthews and Robert A. Winn. Mainstream tobacco control advocates are celebrating the recent announcement that the Food and Drug Administration is poised to restrict the manufacture and sale of mentholated cigarettes and cigars. Free Guest Editorial. MACE ROTHENBERG STEPS DOWN AS PFIZER CMO, REPLACED BY Mace Rothenberg has stepped down as chief medical officer at Pfizer. His successor is Aida Habtezion, a Stanford researcher whose work is focused on leukocyte recruitment and immune responses in diseases affecting the digestive organs.. R othenberg, who served as the Pfizer CMO for two years, announced his move on social media Jan. 4. “Today is my last day as Chief Medical Officer JOE BIDEN HAS AN UNPARALLELED GRASP OF THE SCIENCE AND For the first time in U.S. history, the White House will soon be occupied by a president who has demonstrated a deep understanding of cancer research. In January 2016, seven months after his 42-year-old son, Beau, died from brain cancer, then Vice President Joseph Robinette Biden Jr. became the catalyzing force behind the Moonshot,an
LEONARD B. SALTZ
Ibrutinib is a selective and irreversible inhibitor of Bruton's tyrosine kinase (BTK) that entered phase 1 clinical trials in 2009 based on preclinical efficacy in models of B-cell malignancy and autoimmune disease. The initial phase 1 trial showed clear efficacy in a number of lymphoid malignancies at doses as low as 1.25mg/kg/d.
HOME - THE CANCER LETTEROHIO STATE EXPANDS ASSISTANCE PROGRAM TO GIVE OUT PREVIOUSLY DISPENSED CANCER DRUGSCALENDAR May 14, 2021. May 07, 2021. Apr 30, 2021. View More. The Cancer Letter is an independent weekly news publication and the leading source for information on the issues that shape oncology. SENATE LEADERS SHOW BIPARTISAN SUPPORT FOR BIDEN’S FY22 President Joe Biden is requesting $52 billion in FY2022 for NIH—$9 billion above the enacted FY21 level—of which $6.5 billion is slated for the proposed Advanced Research Projects Agency for Health. While the $9 billion investment, if approved by Congress, would amount to the largest raise in the history of NIH, $2.5 billion of that “1001CUTS”—A GYN ONCOLOGIST EXAMINES THE TOLL OF SEXISM IN The documentary is being completed, and the trailer is available here.The goal is for the film to be released in early 2022. Temkin is raising funds for the production costs here. “When I thought about it, telling a story about the OR made the most sense, and the stories of women and their personal experiences as surgeons in the operating room seemed like the highest impact place to tell the DONALD PINKEL: THE CANCER PIONEER WHO “INTRODUCED THE WORD In collaboration with Donald Pinkel’s daughter, Mary Pinkel, the Cancer History Project is preserving and republishing materials from his personal archive. The documents include acceptance remarks, personal letters, editorials, photographs, video archives, and celebrations of his life’s work. The archive’s index, as well as a conversation between Pinkel and his daughter, appear below ST. JUDE’S $11.5B, SIX-YEAR PLAN AIMS TO IMPROVE GLOBAL Small dreams have no power to move hearts, and in a new six-year strategic plan, St. Jude Children’s Research Hospital is thinking very big. What would it take to drastically increase cure rates for childhood cancer worldwide? St. Jude’s answer: $11.5 billion and an additional 1,400 jobs. To get a rough sense of scale, work CTCA LEAVES TULSA AND PHILADELPHIA; TULSA MOVE COMES AMID “CTCA will continue investing in key markets that will build on more than 30 years of patient-centered, high-quality care.” Philadelphia is a tough market, where CTCA had to compete with three NCI-designated institutions—two of them Comprehensive Cancer Centers—located in the city limits as well as multiple high-quality health systems in theregion.
BREAKING BARRIERS: WOMEN IN ONCOLOGY, LEARNING FROM Philadelphia, where Fox Chase is located, has long been a center for scientific and medical education and research. The first medical school in the United States opened in 1765 at the College of Philadelphia and eventually evolved into the University of Pennsylvania’s Perelman School of Medicine. BIDEN REQUESTS $6.5B TO FUND CANCER-FOCUSED ARPA-H, AN Nathaniel Berlin, an experimental hematologist, joined NCI in 1956 as head of the Metabolism Service in the General Medicine Branch and held that position until 1966, when he became chief of NCI’s Metabolism Branch, a position he held until 1971. ISSUE 18 - THE CANCER LETTER By Phoenix A. Matthews and Robert A. Winn. Mainstream tobacco control advocates are celebrating the recent announcement that the Food and Drug Administration is poised to restrict the manufacture and sale of mentholated cigarettes and cigars. Free Guest Editorial. JANSSEN SUBMITS MARKETING AUTHORIZATION The Janssen Pharmaceutical Companies of Johnson & Johnson has submitted a Marketing Authorization Application to the European Medicines Agency seeking approval of cilta-cel, an investigational B cell maturation antigen (BCMA)-directed chimeric antigen receptor T cell (CAR T) therapy, for the treatment of patients with relapsed and/or refractory multiple myeloma. The HOME - THE CANCER LETTEROHIO STATE EXPANDS ASSISTANCE PROGRAM TO GIVE OUT PREVIOUSLY DISPENSED CANCER DRUGSCALENDAR May 14, 2021. May 07, 2021. Apr 30, 2021. View More. The Cancer Letter is an independent weekly news publication and the leading source for information on the issues that shape oncology. SENATE LEADERS SHOW BIPARTISAN SUPPORT FOR BIDEN’S FY22 President Joe Biden is requesting $52 billion in FY2022 for NIH—$9 billion above the enacted FY21 level—of which $6.5 billion is slated for the proposed Advanced Research Projects Agency for Health. While the $9 billion investment, if approved by Congress, would amount to the largest raise in the history of NIH, $2.5 billion of that “1001CUTS”—A GYN ONCOLOGIST EXAMINES THE TOLL OF SEXISM IN The documentary is being completed, and the trailer is available here.The goal is for the film to be released in early 2022. Temkin is raising funds for the production costs here. “When I thought about it, telling a story about the OR made the most sense, and the stories of women and their personal experiences as surgeons in the operating room seemed like the highest impact place to tell the DONALD PINKEL: THE CANCER PIONEER WHO “INTRODUCED THE WORD In collaboration with Donald Pinkel’s daughter, Mary Pinkel, the Cancer History Project is preserving and republishing materials from his personal archive. The documents include acceptance remarks, personal letters, editorials, photographs, video archives, and celebrations of his life’s work. The archive’s index, as well as a conversation between Pinkel and his daughter, appear below ST. JUDE’S $11.5B, SIX-YEAR PLAN AIMS TO IMPROVE GLOBAL Small dreams have no power to move hearts, and in a new six-year strategic plan, St. Jude Children’s Research Hospital is thinking very big. What would it take to drastically increase cure rates for childhood cancer worldwide? St. Jude’s answer: $11.5 billion and an additional 1,400 jobs. To get a rough sense of scale, work CTCA LEAVES TULSA AND PHILADELPHIA; TULSA MOVE COMES AMID “CTCA will continue investing in key markets that will build on more than 30 years of patient-centered, high-quality care.” Philadelphia is a tough market, where CTCA had to compete with three NCI-designated institutions—two of them Comprehensive Cancer Centers—located in the city limits as well as multiple high-quality health systems in theregion.
BREAKING BARRIERS: WOMEN IN ONCOLOGY, LEARNING FROM Philadelphia, where Fox Chase is located, has long been a center for scientific and medical education and research. The first medical school in the United States opened in 1765 at the College of Philadelphia and eventually evolved into the University of Pennsylvania’s Perelman School of Medicine. BIDEN REQUESTS $6.5B TO FUND CANCER-FOCUSED ARPA-H, AN Nathaniel Berlin, an experimental hematologist, joined NCI in 1956 as head of the Metabolism Service in the General Medicine Branch and held that position until 1966, when he became chief of NCI’s Metabolism Branch, a position he held until 1971. ISSUE 18 - THE CANCER LETTER By Phoenix A. Matthews and Robert A. Winn. Mainstream tobacco control advocates are celebrating the recent announcement that the Food and Drug Administration is poised to restrict the manufacture and sale of mentholated cigarettes and cigars. Free Guest Editorial. JANSSEN SUBMITS MARKETING AUTHORIZATION The Janssen Pharmaceutical Companies of Johnson & Johnson has submitted a Marketing Authorization Application to the European Medicines Agency seeking approval of cilta-cel, an investigational B cell maturation antigen (BCMA)-directed chimeric antigen receptor T cell (CAR T) therapy, for the treatment of patients with relapsed and/or refractory multiple myeloma. TheTHE CANCER LETTER
All issues of The Cancer Letter, from inception in 1973 through the present, are available in our digital archives. SEARCH. SUBSCRIBE - THE CANCER LETTER The Cancer Letter offers a variety of subscriber packages for individuals, groups, and institutions of all sizes. Subscriptions include digital access to all 46 annual issues of The Cancer Letter, special reports, and access to full newsletter archives dating back to1973.
NCI TRIALS FOR MAY 2021 The National Cancer Institute approved the following clinical research studies last month. For further information, contact the principal investigator listed. Phase I – PED-CITN-03 Phase 1 Trial of Hu5F9-G4 (Magrolimab) Combined with Dinutuximab in Children and Young Adults with Relapsed and Refractory Neuroblastoma or Relapsed Osteosarcoma Cancer Immunotherapy Trials Network Majzner, AMERICAN RED CROSS AND AMERICAN CANCER SOCIETY COLLABORATE The American Red Cross and the American Cancer Society are collaborating to encourage people to donate blood for cancer treatment. According to the American Cancer Society, many patient visits and procedures were forced to delay or cancel early in the pandemic to reduce the risk of exposure to COVID-19. With procedures resuming, blood donations are PRECISION ONCOLOGY MUST EVOLVE TO ADDRESS HEALTH Every person facing a cancer diagnosis deserves access to the best possible tests and treatments for their disease. It’s really that simple. Even better—it’s entirely feasible. Biomarker-based cancer therapies are the cornerstone of precision oncology and hold promise for expanding access to the most effective treatment options for every patient. With genomic profiling, we can FDA LAUNCHES CROWDSOURCING CHALLENGE TO SOLICIT INPUT ON FDA’s Oncology Center of Excellence launched the “Send Your Oncology Research Questions to FDA” crowdsourcing challenge. OCE is using this challenge to provide an opportunity for interested stakeholders to submit ideas for research using pooled analyses of oncologic clinical trial data directly to FDA’s scientific staff. ISSUE 18 - THE CANCER LETTER By Phoenix A. Matthews and Robert A. Winn. Mainstream tobacco control advocates are celebrating the recent announcement that the Food and Drug Administration is poised to restrict the manufacture and sale of mentholated cigarettes and cigars. Free Guest Editorial. MACE ROTHENBERG STEPS DOWN AS PFIZER CMO, REPLACED BY Mace Rothenberg has stepped down as chief medical officer at Pfizer. His successor is Aida Habtezion, a Stanford researcher whose work is focused on leukocyte recruitment and immune responses in diseases affecting the digestive organs.. R othenberg, who served as the Pfizer CMO for two years, announced his move on social media Jan. 4. “Today is my last day as Chief Medical Officer JOE BIDEN HAS AN UNPARALLELED GRASP OF THE SCIENCE AND For the first time in U.S. history, the White House will soon be occupied by a president who has demonstrated a deep understanding of cancer research. In January 2016, seven months after his 42-year-old son, Beau, died from brain cancer, then Vice President Joseph Robinette Biden Jr. became the catalyzing force behind the Moonshot,an
LEONARD B. SALTZ
Ibrutinib is a selective and irreversible inhibitor of Bruton's tyrosine kinase (BTK) that entered phase 1 clinical trials in 2009 based on preclinical efficacy in models of B-cell malignancy and autoimmune disease. The initial phase 1 trial showed clear efficacy in a number of lymphoid malignancies at doses as low as 1.25mg/kg/d.
HOME - THE CANCER LETTEROHIO STATE EXPANDS ASSISTANCE PROGRAM TO GIVE OUT PREVIOUSLY DISPENSED CANCER DRUGSCALENDAR May 14, 2021. May 07, 2021. Apr 30, 2021. View More. The Cancer Letter is an independent weekly news publication and the leading source for information on the issues that shape oncology.THE CANCER LETTER
All issues of The Cancer Letter, from inception in 1973 through the present, are available in our digital archives. SEARCH. ST. JUDE’S $11.5B, SIX-YEAR PLAN AIMS TO IMPROVE GLOBAL Small dreams have no power to move hearts, and in a new six-year strategic plan, St. Jude Children’s Research Hospital is thinking very big. What would it take to drastically increase cure rates for childhood cancer worldwide? St. Jude’s answer: $11.5 billion and an additional 1,400 jobs. To get a rough sense of scale, work CTCA LEAVES TULSA AND PHILADELPHIA; TULSA MOVE COMES AMID “CTCA will continue investing in key markets that will build on more than 30 years of patient-centered, high-quality care.” Philadelphia is a tough market, where CTCA had to compete with three NCI-designated institutions—two of them Comprehensive Cancer Centers—located in the city limits as well as multiple high-quality health systems in theregion.
“1001CUTS”—A GYN ONCOLOGIST EXAMINES THE TOLL OF SEXISM IN The documentary is being completed, and the trailer is available here.The goal is for the film to be released in early 2022. Temkin is raising funds for the production costs here. “When I thought about it, telling a story about the OR made the most sense, and the stories of women and their personal experiences as surgeons in the operating room seemed like the highest impact place to tell the ISSUE 18 - THE CANCER LETTER Prominent GI oncologist Axel Grothey was forced out of Mayo Clinic for unethical sexual relationships with women he mentored Three reprimands later, he retains leadership—and mentorship—positions HOW REAL WORLD EVIDENCE WAS USED TO SUPPORT APPROVAL OF We posed the same 10 questions to FDA, Pfizer and Flatiron Health. Here is what came back: The Cancer Letter: Was this the first approval based at least in part on real world evidence in oncology? FDA: Ibrance (palbociclib) was initially approved in 2015. It is a kinase inhibitor, now approved in combination with an A $250M GIFT CREATES BREAK THROUGH CANCER FOUNDATION TO Five academic cancer centers have formed a unique research alliance, Break Through Cancer, to focus on four cancer types—pancreatic cancer, ovarian cancer, glioblastoma, and acute myelogenous leukemia. The founding members of Break Through Cancer are Dana-Farber Cancer Institute, the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The University of Texas MACE ROTHENBERG STEPS DOWN AS PFIZER CMO, REPLACED BY Mace Rothenberg has stepped down as chief medical officer at Pfizer. His successor is Aida Habtezion, a Stanford researcher whose work is focused on leukocyte recruitment and immune responses in diseases affecting the digestive organs. Rothenberg, who served as the Pfizer CMO for two years, announced his move on social media Jan. 4. “Todayis
PANCREATIC CANCER CONVERGENCE DREAM TEAM TO STUDY Pancreatic Cancer Convergence Dream Team to study pancreatic cancer tumor traits. UCLA study: Percutaneous image guided thermal ablation safe, effective therapy for metastatic gynecologic cancers. Low-dose aspirin use prior to diagnosis of colorectal cancer is associated with better survival outcomes. Drugs & Targets. HOME - THE CANCER LETTEROHIO STATE EXPANDS ASSISTANCE PROGRAM TO GIVE OUT PREVIOUSLY DISPENSED CANCER DRUGSCALENDAR May 14, 2021. May 07, 2021. Apr 30, 2021. View More. The Cancer Letter is an independent weekly news publication and the leading source for information on the issues that shape oncology.THE CANCER LETTER
All issues of The Cancer Letter, from inception in 1973 through the present, are available in our digital archives. SEARCH. ST. JUDE’S $11.5B, SIX-YEAR PLAN AIMS TO IMPROVE GLOBAL Small dreams have no power to move hearts, and in a new six-year strategic plan, St. Jude Children’s Research Hospital is thinking very big. What would it take to drastically increase cure rates for childhood cancer worldwide? St. Jude’s answer: $11.5 billion and an additional 1,400 jobs. To get a rough sense of scale, work CTCA LEAVES TULSA AND PHILADELPHIA; TULSA MOVE COMES AMID “CTCA will continue investing in key markets that will build on more than 30 years of patient-centered, high-quality care.” Philadelphia is a tough market, where CTCA had to compete with three NCI-designated institutions—two of them Comprehensive Cancer Centers—located in the city limits as well as multiple high-quality health systems in theregion.
“1001CUTS”—A GYN ONCOLOGIST EXAMINES THE TOLL OF SEXISM IN The documentary is being completed, and the trailer is available here.The goal is for the film to be released in early 2022. Temkin is raising funds for the production costs here. “When I thought about it, telling a story about the OR made the most sense, and the stories of women and their personal experiences as surgeons in the operating room seemed like the highest impact place to tell the ISSUE 18 - THE CANCER LETTER Prominent GI oncologist Axel Grothey was forced out of Mayo Clinic for unethical sexual relationships with women he mentored Three reprimands later, he retains leadership—and mentorship—positions HOW REAL WORLD EVIDENCE WAS USED TO SUPPORT APPROVAL OF We posed the same 10 questions to FDA, Pfizer and Flatiron Health. Here is what came back: The Cancer Letter: Was this the first approval based at least in part on real world evidence in oncology? FDA: Ibrance (palbociclib) was initially approved in 2015. It is a kinase inhibitor, now approved in combination with an A $250M GIFT CREATES BREAK THROUGH CANCER FOUNDATION TO Five academic cancer centers have formed a unique research alliance, Break Through Cancer, to focus on four cancer types—pancreatic cancer, ovarian cancer, glioblastoma, and acute myelogenous leukemia. The founding members of Break Through Cancer are Dana-Farber Cancer Institute, the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The University of Texas MACE ROTHENBERG STEPS DOWN AS PFIZER CMO, REPLACED BY Mace Rothenberg has stepped down as chief medical officer at Pfizer. His successor is Aida Habtezion, a Stanford researcher whose work is focused on leukocyte recruitment and immune responses in diseases affecting the digestive organs. Rothenberg, who served as the Pfizer CMO for two years, announced his move on social media Jan. 4. “Todayis
PANCREATIC CANCER CONVERGENCE DREAM TEAM TO STUDY Pancreatic Cancer Convergence Dream Team to study pancreatic cancer tumor traits. UCLA study: Percutaneous image guided thermal ablation safe, effective therapy for metastatic gynecologic cancers. Low-dose aspirin use prior to diagnosis of colorectal cancer is associated with better survival outcomes. Drugs & Targets.OUR READERS
The Cancer Letter reaches key opinion leaders across disciplines and professional societies: in clinical practice, basic science, academic centers, community oncology, the biotechnology and pharmaceutical industries, health IT, the government, advocacy, the legal profession, and Wall Street. A searchable list of our institutional subscribers isavailable below.
SUBSCRIBE - THE CANCER LETTER In-depth and award-winning coverage of the issues that impact oncology. Access to over 2,000 back issues of The Cancer Letter, dating back to 1973. Exclusive commentary from top-tier oncology thought leaders and experts. Usage statistics reports to assess how frequently your faculty and staff are reading The Cancer Letter. AS AXEL GROTHEY BECOMES AN EMBLEM OF SEXUAL MISCONDUCT IN Inappropriate sexual relationships of the sort Axel Grothey engaged in at Mayo Clinic may be all too common. The Grothey case is unique, because it has slipped out from under the cloak of confidentiality, making Grothey into a symbol of sexual misconduct, including abuse of power in the relationship between mentor and mentee. The Cancer “1001CUTS”—A GYN ONCOLOGIST EXAMINES THE TOLL OF SEXISM IN The documentary is being completed, and the trailer is available here.The goal is for the film to be released in early 2022. Temkin is raising funds for the production costs here. “When I thought about it, telling a story about the OR made the most sense, and the stories of women and their personal experiences as surgeons in the operating room seemed like the highest impact place to tell the LUMAKRAS RECEIVES FDA ACCELERATED APPROVAL FOR KRAS G12C FDA has granted accelerated approval to Lumakras (sotorasib) a RAS GTPase family inhibitor, for adult patients with KRAS G12C ‑mutated locally advanced or metastatic non-small cell lung cancer, as determined by an FDA ‑approved test, who have received at least one prior systemic therapy. Lumakras is sponsored by Amgen. FDA also approved the Qiagen therascreen SENATE LEADERS SHOW BIPARTISAN SUPPORT FOR BIDEN’S FY22 President Joe Biden is requesting $52 billion in FY2022 for NIH—$9 billion above the enacted FY21 level—of which $6.5 billion is slated for the proposed Advanced Research Projects Agency for Health. While the $9 billion investment, if approved by Congress, would amount to the largest raise in the history of NIH, $2.5 billion of that TRUSELTIQ RECEIVES FDA ACCELERATED APPROVAL FOR METASTATIC Truseltiq (Infigratinib) a kinase inhibitor for adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 fusion or other rearrangement as detected by an FDA-approved test. Truseltiq is sponsored by BridgeBio Pharma/QED Therapeutics and Helsinn Group. FDA also approved FoundationOne CDx (Foundation PRECISION ONCOLOGY MUST EVOLVE TO ADDRESS HEALTH Every person facing a cancer diagnosis deserves access to the best possible tests and treatments for their disease. It’s really that simple. Even better—it’s entirely feasible. Biomarker-based cancer therapies are the cornerstone of precision oncology and hold promise for expanding access to the most effective treatment options for every patient. With genomic profiling, we can AMERICAN RED CROSS AND AMERICAN CANCER SOCIETY COLLABORATE The American Red Cross and the American Cancer Society are collaborating to encourage people to donate blood for cancer treatment. According to the American Cancer Society, many patient visits and procedures were forced to delay or cancel early in the pandemic to reduce the risk of exposure to COVID-19. With procedures resuming, blood donations are BREAKING NEW GROUND: NATHANIEL BERLIN, PAUL MARKS, AND VAL Nathaniel Berlin on the Diagnostic Radiology Program Nathaniel Berlin, an experimental hematologist, joined NCI in 1956 as head of the Metabolism Service in the General Medicine Branch and held that position until 1966, when he became chief of NCI’s Metabolism Branch, a position he held until 1971. This interview was conducted by History Associates Incorporated HOME - THE CANCER LETTEROHIO STATE EXPANDS ASSISTANCE PROGRAM TO GIVE OUT PREVIOUSLY DISPENSED CANCER DRUGSCALENDAR May 14, 2021. May 07, 2021. Apr 30, 2021. View More. The Cancer Letter is an independent weekly news publication and the leading source for information on the issues that shape oncology.THE CANCER LETTER
All issues of The Cancer Letter, from inception in 1973 through the present, are available in our digital archives. SEARCH. ST. JUDE’S $11.5B, SIX-YEAR PLAN AIMS TO IMPROVE GLOBAL Small dreams have no power to move hearts, and in a new six-year strategic plan, St. Jude Children’s Research Hospital is thinking very big. What would it take to drastically increase cure rates for childhood cancer worldwide? St. Jude’s answer: $11.5 billion and an additional 1,400 jobs. To get a rough sense of scale, work CTCA LEAVES TULSA AND PHILADELPHIA; TULSA MOVE COMES AMID “CTCA will continue investing in key markets that will build on more than 30 years of patient-centered, high-quality care.” Philadelphia is a tough market, where CTCA had to compete with three NCI-designated institutions—two of them Comprehensive Cancer Centers—located in the city limits as well as multiple high-quality health systems in theregion.
“1001CUTS”—A GYN ONCOLOGIST EXAMINES THE TOLL OF SEXISM IN The documentary is being completed, and the trailer is available here.The goal is for the film to be released in early 2022. Temkin is raising funds for the production costs here. “When I thought about it, telling a story about the OR made the most sense, and the stories of women and their personal experiences as surgeons in the operating room seemed like the highest impact place to tell the ISSUE 18 - THE CANCER LETTER Prominent GI oncologist Axel Grothey was forced out of Mayo Clinic for unethical sexual relationships with women he mentored Three reprimands later, he retains leadership—and mentorship—positions HOW REAL WORLD EVIDENCE WAS USED TO SUPPORT APPROVAL OF We posed the same 10 questions to FDA, Pfizer and Flatiron Health. Here is what came back: The Cancer Letter: Was this the first approval based at least in part on real world evidence in oncology? FDA: Ibrance (palbociclib) was initially approved in 2015. It is a kinase inhibitor, now approved in combination with an A $250M GIFT CREATES BREAK THROUGH CANCER FOUNDATION TO Five academic cancer centers have formed a unique research alliance, Break Through Cancer, to focus on four cancer types—pancreatic cancer, ovarian cancer, glioblastoma, and acute myelogenous leukemia. The founding members of Break Through Cancer are Dana-Farber Cancer Institute, the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The University of Texas MACE ROTHENBERG STEPS DOWN AS PFIZER CMO, REPLACED BY Mace Rothenberg has stepped down as chief medical officer at Pfizer. His successor is Aida Habtezion, a Stanford researcher whose work is focused on leukocyte recruitment and immune responses in diseases affecting the digestive organs. Rothenberg, who served as the Pfizer CMO for two years, announced his move on social media Jan. 4. “Todayis
PANCREATIC CANCER CONVERGENCE DREAM TEAM TO STUDY Pancreatic Cancer Convergence Dream Team to study pancreatic cancer tumor traits. UCLA study: Percutaneous image guided thermal ablation safe, effective therapy for metastatic gynecologic cancers. Low-dose aspirin use prior to diagnosis of colorectal cancer is associated with better survival outcomes. Drugs & Targets. HOME - THE CANCER LETTEROHIO STATE EXPANDS ASSISTANCE PROGRAM TO GIVE OUT PREVIOUSLY DISPENSED CANCER DRUGSCALENDAR May 14, 2021. May 07, 2021. Apr 30, 2021. View More. The Cancer Letter is an independent weekly news publication and the leading source for information on the issues that shape oncology.THE CANCER LETTER
All issues of The Cancer Letter, from inception in 1973 through the present, are available in our digital archives. SEARCH. ST. JUDE’S $11.5B, SIX-YEAR PLAN AIMS TO IMPROVE GLOBAL Small dreams have no power to move hearts, and in a new six-year strategic plan, St. Jude Children’s Research Hospital is thinking very big. What would it take to drastically increase cure rates for childhood cancer worldwide? St. Jude’s answer: $11.5 billion and an additional 1,400 jobs. To get a rough sense of scale, work CTCA LEAVES TULSA AND PHILADELPHIA; TULSA MOVE COMES AMID “CTCA will continue investing in key markets that will build on more than 30 years of patient-centered, high-quality care.” Philadelphia is a tough market, where CTCA had to compete with three NCI-designated institutions—two of them Comprehensive Cancer Centers—located in the city limits as well as multiple high-quality health systems in theregion.
“1001CUTS”—A GYN ONCOLOGIST EXAMINES THE TOLL OF SEXISM IN The documentary is being completed, and the trailer is available here.The goal is for the film to be released in early 2022. Temkin is raising funds for the production costs here. “When I thought about it, telling a story about the OR made the most sense, and the stories of women and their personal experiences as surgeons in the operating room seemed like the highest impact place to tell the ISSUE 18 - THE CANCER LETTER Prominent GI oncologist Axel Grothey was forced out of Mayo Clinic for unethical sexual relationships with women he mentored Three reprimands later, he retains leadership—and mentorship—positions HOW REAL WORLD EVIDENCE WAS USED TO SUPPORT APPROVAL OF We posed the same 10 questions to FDA, Pfizer and Flatiron Health. Here is what came back: The Cancer Letter: Was this the first approval based at least in part on real world evidence in oncology? FDA: Ibrance (palbociclib) was initially approved in 2015. It is a kinase inhibitor, now approved in combination with an A $250M GIFT CREATES BREAK THROUGH CANCER FOUNDATION TO Five academic cancer centers have formed a unique research alliance, Break Through Cancer, to focus on four cancer types—pancreatic cancer, ovarian cancer, glioblastoma, and acute myelogenous leukemia. The founding members of Break Through Cancer are Dana-Farber Cancer Institute, the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The University of Texas MACE ROTHENBERG STEPS DOWN AS PFIZER CMO, REPLACED BY Mace Rothenberg has stepped down as chief medical officer at Pfizer. His successor is Aida Habtezion, a Stanford researcher whose work is focused on leukocyte recruitment and immune responses in diseases affecting the digestive organs. Rothenberg, who served as the Pfizer CMO for two years, announced his move on social media Jan. 4. “Todayis
PANCREATIC CANCER CONVERGENCE DREAM TEAM TO STUDY Pancreatic Cancer Convergence Dream Team to study pancreatic cancer tumor traits. UCLA study: Percutaneous image guided thermal ablation safe, effective therapy for metastatic gynecologic cancers. Low-dose aspirin use prior to diagnosis of colorectal cancer is associated with better survival outcomes. Drugs & Targets. SUBSCRIBE - THE CANCER LETTER In-depth and award-winning coverage of the issues that impact oncology. Access to over 2,000 back issues of The Cancer Letter, dating back to 1973. Exclusive commentary from top-tier oncology thought leaders and experts. Usage statistics reports to assess how frequently your faculty and staff are reading The Cancer Letter.OUR READERS
The Cancer Letter reaches key opinion leaders across disciplines and professional societies: in clinical practice, basic science, academic centers, community oncology, the biotechnology and pharmaceutical industries, health IT, the government, advocacy, the legal profession, and Wall Street. A searchable list of our institutional subscribers isavailable below.
AS AXEL GROTHEY BECOMES AN EMBLEM OF SEXUAL MISCONDUCT IN Inappropriate sexual relationships of the sort Axel Grothey engaged in at Mayo Clinic may be all too common. The Grothey case is unique, because it has slipped out from under the cloak of confidentiality, making Grothey into a symbol of sexual misconduct, including abuse of power in the relationship between mentor and mentee. The Cancer “1001CUTS”—A GYN ONCOLOGIST EXAMINES THE TOLL OF SEXISM IN The documentary is being completed, and the trailer is available here.The goal is for the film to be released in early 2022. Temkin is raising funds for the production costs here. “When I thought about it, telling a story about the OR made the most sense, and the stories of women and their personal experiences as surgeons in the operating room seemed like the highest impact place to tell the LUMAKRAS RECEIVES FDA ACCELERATED APPROVAL FOR KRAS G12C FDA has granted accelerated approval to Lumakras (sotorasib) a RAS GTPase family inhibitor, for adult patients with KRAS G12C ‑mutated locally advanced or metastatic non-small cell lung cancer, as determined by an FDA ‑approved test, who have received at least one prior systemic therapy. Lumakras is sponsored by Amgen. FDA also approved the Qiagen therascreen SENATE LEADERS SHOW BIPARTISAN SUPPORT FOR BIDEN’S FY22 President Joe Biden is requesting $52 billion in FY2022 for NIH—$9 billion above the enacted FY21 level—of which $6.5 billion is slated for the proposed Advanced Research Projects Agency for Health. While the $9 billion investment, if approved by Congress, would amount to the largest raise in the history of NIH, $2.5 billion of that TRUSELTIQ RECEIVES FDA ACCELERATED APPROVAL FOR METASTATIC Truseltiq (Infigratinib) a kinase inhibitor for adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 fusion or other rearrangement as detected by an FDA-approved test. Truseltiq is sponsored by BridgeBio Pharma/QED Therapeutics and Helsinn Group. FDA also approved FoundationOne CDx (Foundation PRECISION ONCOLOGY MUST EVOLVE TO ADDRESS HEALTH Every person facing a cancer diagnosis deserves access to the best possible tests and treatments for their disease. It’s really that simple. Even better—it’s entirely feasible. Biomarker-based cancer therapies are the cornerstone of precision oncology and hold promise for expanding access to the most effective treatment options for every patient. With genomic profiling, we can AMERICAN RED CROSS AND AMERICAN CANCER SOCIETY COLLABORATE The American Red Cross and the American Cancer Society are collaborating to encourage people to donate blood for cancer treatment. According to the American Cancer Society, many patient visits and procedures were forced to delay or cancel early in the pandemic to reduce the risk of exposure to COVID-19. With procedures resuming, blood donations are BREAKING NEW GROUND: NATHANIEL BERLIN, PAUL MARKS, AND VAL Nathaniel Berlin on the Diagnostic Radiology Program Nathaniel Berlin, an experimental hematologist, joined NCI in 1956 as head of the Metabolism Service in the General Medicine Branch and held that position until 1966, when he became chief of NCI’s Metabolism Branch, a position he held until 1971. This interview was conducted by History Associates Incorporated HOME - THE CANCER LETTEROHIO STATE EXPANDS ASSISTANCE PROGRAM TO GIVE OUT PREVIOUSLY DISPENSED CANCER DRUGSCALENDAR May 14, 2021. May 07, 2021. Apr 30, 2021. View More. The Cancer Letter is an independent weekly news publication and the leading source for information on the issues that shape oncology.THE CANCER LETTER
All issues of The Cancer Letter, from inception in 1973 through the present, are available in our digital archives. SEARCH. ST. JUDE’S $11.5B, SIX-YEAR PLAN AIMS TO IMPROVE GLOBAL Small dreams have no power to move hearts, and in a new six-year strategic plan, St. Jude Children’s Research Hospital is thinking very big. What would it take to drastically increase cure rates for childhood cancer worldwide? St. Jude’s answer: $11.5 billion and an additional 1,400 jobs. To get a rough sense of scale, work CTCA LEAVES TULSA AND PHILADELPHIA; TULSA MOVE COMES AMID “CTCA will continue investing in key markets that will build on more than 30 years of patient-centered, high-quality care.” Philadelphia is a tough market, where CTCA had to compete with three NCI-designated institutions—two of them Comprehensive Cancer Centers—located in the city limits as well as multiple high-quality health systems in theregion.
“1001CUTS”—A GYN ONCOLOGIST EXAMINES THE TOLL OF SEXISM IN The documentary is being completed, and the trailer is available here.The goal is for the film to be released in early 2022. Temkin is raising funds for the production costs here. “When I thought about it, telling a story about the OR made the most sense, and the stories of women and their personal experiences as surgeons in the operating room seemed like the highest impact place to tell the ISSUE 18 - THE CANCER LETTER Prominent GI oncologist Axel Grothey was forced out of Mayo Clinic for unethical sexual relationships with women he mentored Three reprimands later, he retains leadership—and mentorship—positions HOW REAL WORLD EVIDENCE WAS USED TO SUPPORT APPROVAL OF We posed the same 10 questions to FDA, Pfizer and Flatiron Health. Here is what came back: The Cancer Letter: Was this the first approval based at least in part on real world evidence in oncology? FDA: Ibrance (palbociclib) was initially approved in 2015. It is a kinase inhibitor, now approved in combination with an A $250M GIFT CREATES BREAK THROUGH CANCER FOUNDATION TO Five academic cancer centers have formed a unique research alliance, Break Through Cancer, to focus on four cancer types—pancreatic cancer, ovarian cancer, glioblastoma, and acute myelogenous leukemia. The founding members of Break Through Cancer are Dana-Farber Cancer Institute, the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The University of Texas MACE ROTHENBERG STEPS DOWN AS PFIZER CMO, REPLACED BY Mace Rothenberg has stepped down as chief medical officer at Pfizer. His successor is Aida Habtezion, a Stanford researcher whose work is focused on leukocyte recruitment and immune responses in diseases affecting the digestive organs. Rothenberg, who served as the Pfizer CMO for two years, announced his move on social media Jan. 4. “Todayis
PANCREATIC CANCER CONVERGENCE DREAM TEAM TO STUDY Pancreatic Cancer Convergence Dream Team to study pancreatic cancer tumor traits. UCLA study: Percutaneous image guided thermal ablation safe, effective therapy for metastatic gynecologic cancers. Low-dose aspirin use prior to diagnosis of colorectal cancer is associated with better survival outcomes. Drugs & Targets. HOME - THE CANCER LETTEROHIO STATE EXPANDS ASSISTANCE PROGRAM TO GIVE OUT PREVIOUSLY DISPENSED CANCER DRUGSCALENDAR May 14, 2021. May 07, 2021. Apr 30, 2021. View More. The Cancer Letter is an independent weekly news publication and the leading source for information on the issues that shape oncology.THE CANCER LETTER
All issues of The Cancer Letter, from inception in 1973 through the present, are available in our digital archives. SEARCH. ST. JUDE’S $11.5B, SIX-YEAR PLAN AIMS TO IMPROVE GLOBAL Small dreams have no power to move hearts, and in a new six-year strategic plan, St. Jude Children’s Research Hospital is thinking very big. What would it take to drastically increase cure rates for childhood cancer worldwide? St. Jude’s answer: $11.5 billion and an additional 1,400 jobs. To get a rough sense of scale, work CTCA LEAVES TULSA AND PHILADELPHIA; TULSA MOVE COMES AMID “CTCA will continue investing in key markets that will build on more than 30 years of patient-centered, high-quality care.” Philadelphia is a tough market, where CTCA had to compete with three NCI-designated institutions—two of them Comprehensive Cancer Centers—located in the city limits as well as multiple high-quality health systems in theregion.
“1001CUTS”—A GYN ONCOLOGIST EXAMINES THE TOLL OF SEXISM IN The documentary is being completed, and the trailer is available here.The goal is for the film to be released in early 2022. Temkin is raising funds for the production costs here. “When I thought about it, telling a story about the OR made the most sense, and the stories of women and their personal experiences as surgeons in the operating room seemed like the highest impact place to tell the ISSUE 18 - THE CANCER LETTER Prominent GI oncologist Axel Grothey was forced out of Mayo Clinic for unethical sexual relationships with women he mentored Three reprimands later, he retains leadership—and mentorship—positions HOW REAL WORLD EVIDENCE WAS USED TO SUPPORT APPROVAL OF We posed the same 10 questions to FDA, Pfizer and Flatiron Health. Here is what came back: The Cancer Letter: Was this the first approval based at least in part on real world evidence in oncology? FDA: Ibrance (palbociclib) was initially approved in 2015. It is a kinase inhibitor, now approved in combination with an A $250M GIFT CREATES BREAK THROUGH CANCER FOUNDATION TO Five academic cancer centers have formed a unique research alliance, Break Through Cancer, to focus on four cancer types—pancreatic cancer, ovarian cancer, glioblastoma, and acute myelogenous leukemia. The founding members of Break Through Cancer are Dana-Farber Cancer Institute, the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The University of Texas MACE ROTHENBERG STEPS DOWN AS PFIZER CMO, REPLACED BY Mace Rothenberg has stepped down as chief medical officer at Pfizer. His successor is Aida Habtezion, a Stanford researcher whose work is focused on leukocyte recruitment and immune responses in diseases affecting the digestive organs. Rothenberg, who served as the Pfizer CMO for two years, announced his move on social media Jan. 4. “Todayis
PANCREATIC CANCER CONVERGENCE DREAM TEAM TO STUDY Pancreatic Cancer Convergence Dream Team to study pancreatic cancer tumor traits. UCLA study: Percutaneous image guided thermal ablation safe, effective therapy for metastatic gynecologic cancers. Low-dose aspirin use prior to diagnosis of colorectal cancer is associated with better survival outcomes. Drugs & Targets. SUBSCRIBE - THE CANCER LETTER In-depth and award-winning coverage of the issues that impact oncology. Access to over 2,000 back issues of The Cancer Letter, dating back to 1973. Exclusive commentary from top-tier oncology thought leaders and experts. Usage statistics reports to assess how frequently your faculty and staff are reading The Cancer Letter.OUR READERS
The Cancer Letter reaches key opinion leaders across disciplines and professional societies: in clinical practice, basic science, academic centers, community oncology, the biotechnology and pharmaceutical industries, health IT, the government, advocacy, the legal profession, and Wall Street. A searchable list of our institutional subscribers isavailable below.
AS AXEL GROTHEY BECOMES AN EMBLEM OF SEXUAL MISCONDUCT IN Inappropriate sexual relationships of the sort Axel Grothey engaged in at Mayo Clinic may be all too common. The Grothey case is unique, because it has slipped out from under the cloak of confidentiality, making Grothey into a symbol of sexual misconduct, including abuse of power in the relationship between mentor and mentee. The Cancer “1001CUTS”—A GYN ONCOLOGIST EXAMINES THE TOLL OF SEXISM IN The documentary is being completed, and the trailer is available here.The goal is for the film to be released in early 2022. Temkin is raising funds for the production costs here. “When I thought about it, telling a story about the OR made the most sense, and the stories of women and their personal experiences as surgeons in the operating room seemed like the highest impact place to tell the LUMAKRAS RECEIVES FDA ACCELERATED APPROVAL FOR KRAS G12C FDA has granted accelerated approval to Lumakras (sotorasib) a RAS GTPase family inhibitor, for adult patients with KRAS G12C ‑mutated locally advanced or metastatic non-small cell lung cancer, as determined by an FDA ‑approved test, who have received at least one prior systemic therapy. Lumakras is sponsored by Amgen. FDA also approved the Qiagen therascreen SENATE LEADERS SHOW BIPARTISAN SUPPORT FOR BIDEN’S FY22 President Joe Biden is requesting $52 billion in FY2022 for NIH—$9 billion above the enacted FY21 level—of which $6.5 billion is slated for the proposed Advanced Research Projects Agency for Health. While the $9 billion investment, if approved by Congress, would amount to the largest raise in the history of NIH, $2.5 billion of that TRUSELTIQ RECEIVES FDA ACCELERATED APPROVAL FOR METASTATIC Truseltiq (Infigratinib) a kinase inhibitor for adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 fusion or other rearrangement as detected by an FDA-approved test. Truseltiq is sponsored by BridgeBio Pharma/QED Therapeutics and Helsinn Group. FDA also approved FoundationOne CDx (Foundation PRECISION ONCOLOGY MUST EVOLVE TO ADDRESS HEALTH Every person facing a cancer diagnosis deserves access to the best possible tests and treatments for their disease. It’s really that simple. Even better—it’s entirely feasible. Biomarker-based cancer therapies are the cornerstone of precision oncology and hold promise for expanding access to the most effective treatment options for every patient. With genomic profiling, we can AMERICAN RED CROSS AND AMERICAN CANCER SOCIETY COLLABORATE The American Red Cross and the American Cancer Society are collaborating to encourage people to donate blood for cancer treatment. According to the American Cancer Society, many patient visits and procedures were forced to delay or cancel early in the pandemic to reduce the risk of exposure to COVID-19. With procedures resuming, blood donations are BREAKING NEW GROUND: NATHANIEL BERLIN, PAUL MARKS, AND VAL Nathaniel Berlin on the Diagnostic Radiology Program Nathaniel Berlin, an experimental hematologist, joined NCI in 1956 as head of the Metabolism Service in the General Medicine Branch and held that position until 1966, when he became chief of NCI’s Metabolism Branch, a position he held until 1971. This interview was conducted by History Associates Incorporated HOME - THE CANCER LETTEROHIO STATE EXPANDS ASSISTANCE PROGRAM TO GIVE OUT PREVIOUSLY DISPENSED CANCER DRUGSCALENDAR May 14, 2021. May 07, 2021. Apr 30, 2021. View More. The Cancer Letter is an independent weekly news publication and the leading source for information on the issues that shape oncology.THE CANCER LETTER
All issues of The Cancer Letter, from inception in 1973 through the present, are available in our digital archives. SEARCH. ST. JUDE’S $11.5B, SIX-YEAR PLAN AIMS TO IMPROVE GLOBAL Small dreams have no power to move hearts, and in a new six-year strategic plan, St. Jude Children’s Research Hospital is thinking very big. What would it take to drastically increase cure rates for childhood cancer worldwide? St. Jude’s answer: $11.5 billion and an additional 1,400 jobs. To get a rough sense of scale, work CTCA LEAVES TULSA AND PHILADELPHIA; TULSA MOVE COMES AMID “CTCA will continue investing in key markets that will build on more than 30 years of patient-centered, high-quality care.” Philadelphia is a tough market, where CTCA had to compete with three NCI-designated institutions—two of them Comprehensive Cancer Centers—located in the city limits as well as multiple high-quality health systems in theregion.
“1001CUTS”—A GYN ONCOLOGIST EXAMINES THE TOLL OF SEXISM IN The documentary is being completed, and the trailer is available here.The goal is for the film to be released in early 2022. Temkin is raising funds for the production costs here. “When I thought about it, telling a story about the OR made the most sense, and the stories of women and their personal experiences as surgeons in the operating room seemed like the highest impact place to tell the ISSUE 18 - THE CANCER LETTER Prominent GI oncologist Axel Grothey was forced out of Mayo Clinic for unethical sexual relationships with women he mentored Three reprimands later, he retains leadership—and mentorship—positions HOW REAL WORLD EVIDENCE WAS USED TO SUPPORT APPROVAL OF We posed the same 10 questions to FDA, Pfizer and Flatiron Health. Here is what came back: The Cancer Letter: Was this the first approval based at least in part on real world evidence in oncology? FDA: Ibrance (palbociclib) was initially approved in 2015. It is a kinase inhibitor, now approved in combination with an A $250M GIFT CREATES BREAK THROUGH CANCER FOUNDATION TO Five academic cancer centers have formed a unique research alliance, Break Through Cancer, to focus on four cancer types—pancreatic cancer, ovarian cancer, glioblastoma, and acute myelogenous leukemia. The founding members of Break Through Cancer are Dana-Farber Cancer Institute, the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The University of Texas MACE ROTHENBERG STEPS DOWN AS PFIZER CMO, REPLACED BY Mace Rothenberg has stepped down as chief medical officer at Pfizer. His successor is Aida Habtezion, a Stanford researcher whose work is focused on leukocyte recruitment and immune responses in diseases affecting the digestive organs. Rothenberg, who served as the Pfizer CMO for two years, announced his move on social media Jan. 4. “Todayis
PANCREATIC CANCER CONVERGENCE DREAM TEAM TO STUDY Pancreatic Cancer Convergence Dream Team to study pancreatic cancer tumor traits. UCLA study: Percutaneous image guided thermal ablation safe, effective therapy for metastatic gynecologic cancers. Low-dose aspirin use prior to diagnosis of colorectal cancer is associated with better survival outcomes. Drugs & Targets. HOME - THE CANCER LETTEROHIO STATE EXPANDS ASSISTANCE PROGRAM TO GIVE OUT PREVIOUSLY DISPENSED CANCER DRUGSCALENDAR May 14, 2021. May 07, 2021. Apr 30, 2021. View More. The Cancer Letter is an independent weekly news publication and the leading source for information on the issues that shape oncology.THE CANCER LETTER
All issues of The Cancer Letter, from inception in 1973 through the present, are available in our digital archives. SEARCH. ST. JUDE’S $11.5B, SIX-YEAR PLAN AIMS TO IMPROVE GLOBAL Small dreams have no power to move hearts, and in a new six-year strategic plan, St. Jude Children’s Research Hospital is thinking very big. What would it take to drastically increase cure rates for childhood cancer worldwide? St. Jude’s answer: $11.5 billion and an additional 1,400 jobs. To get a rough sense of scale, work CTCA LEAVES TULSA AND PHILADELPHIA; TULSA MOVE COMES AMID “CTCA will continue investing in key markets that will build on more than 30 years of patient-centered, high-quality care.” Philadelphia is a tough market, where CTCA had to compete with three NCI-designated institutions—two of them Comprehensive Cancer Centers—located in the city limits as well as multiple high-quality health systems in theregion.
“1001CUTS”—A GYN ONCOLOGIST EXAMINES THE TOLL OF SEXISM IN The documentary is being completed, and the trailer is available here.The goal is for the film to be released in early 2022. Temkin is raising funds for the production costs here. “When I thought about it, telling a story about the OR made the most sense, and the stories of women and their personal experiences as surgeons in the operating room seemed like the highest impact place to tell the ISSUE 18 - THE CANCER LETTER Prominent GI oncologist Axel Grothey was forced out of Mayo Clinic for unethical sexual relationships with women he mentored Three reprimands later, he retains leadership—and mentorship—positions HOW REAL WORLD EVIDENCE WAS USED TO SUPPORT APPROVAL OF We posed the same 10 questions to FDA, Pfizer and Flatiron Health. Here is what came back: The Cancer Letter: Was this the first approval based at least in part on real world evidence in oncology? FDA: Ibrance (palbociclib) was initially approved in 2015. It is a kinase inhibitor, now approved in combination with an A $250M GIFT CREATES BREAK THROUGH CANCER FOUNDATION TO Five academic cancer centers have formed a unique research alliance, Break Through Cancer, to focus on four cancer types—pancreatic cancer, ovarian cancer, glioblastoma, and acute myelogenous leukemia. The founding members of Break Through Cancer are Dana-Farber Cancer Institute, the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The University of Texas MACE ROTHENBERG STEPS DOWN AS PFIZER CMO, REPLACED BY Mace Rothenberg has stepped down as chief medical officer at Pfizer. His successor is Aida Habtezion, a Stanford researcher whose work is focused on leukocyte recruitment and immune responses in diseases affecting the digestive organs. Rothenberg, who served as the Pfizer CMO for two years, announced his move on social media Jan. 4. “Todayis
PANCREATIC CANCER CONVERGENCE DREAM TEAM TO STUDY Pancreatic Cancer Convergence Dream Team to study pancreatic cancer tumor traits. UCLA study: Percutaneous image guided thermal ablation safe, effective therapy for metastatic gynecologic cancers. Low-dose aspirin use prior to diagnosis of colorectal cancer is associated with better survival outcomes. Drugs & Targets. SUBSCRIBE - THE CANCER LETTER In-depth and award-winning coverage of the issues that impact oncology. Access to over 2,000 back issues of The Cancer Letter, dating back to 1973. Exclusive commentary from top-tier oncology thought leaders and experts. Usage statistics reports to assess how frequently your faculty and staff are reading The Cancer Letter.OUR READERS
The Cancer Letter reaches key opinion leaders across disciplines and professional societies: in clinical practice, basic science, academic centers, community oncology, the biotechnology and pharmaceutical industries, health IT, the government, advocacy, the legal profession, and Wall Street. A searchable list of our institutional subscribers isavailable below.
AS AXEL GROTHEY BECOMES AN EMBLEM OF SEXUAL MISCONDUCT IN Inappropriate sexual relationships of the sort Axel Grothey engaged in at Mayo Clinic may be all too common. The Grothey case is unique, because it has slipped out from under the cloak of confidentiality, making Grothey into a symbol of sexual misconduct, including abuse of power in the relationship between mentor and mentee. The Cancer “1001CUTS”—A GYN ONCOLOGIST EXAMINES THE TOLL OF SEXISM IN The documentary is being completed, and the trailer is available here.The goal is for the film to be released in early 2022. Temkin is raising funds for the production costs here. “When I thought about it, telling a story about the OR made the most sense, and the stories of women and their personal experiences as surgeons in the operating room seemed like the highest impact place to tell the LUMAKRAS RECEIVES FDA ACCELERATED APPROVAL FOR KRAS G12C FDA has granted accelerated approval to Lumakras (sotorasib) a RAS GTPase family inhibitor, for adult patients with KRAS G12C ‑mutated locally advanced or metastatic non-small cell lung cancer, as determined by an FDA ‑approved test, who have received at least one prior systemic therapy. Lumakras is sponsored by Amgen. FDA also approved the Qiagen therascreen SENATE LEADERS SHOW BIPARTISAN SUPPORT FOR BIDEN’S FY22 President Joe Biden is requesting $52 billion in FY2022 for NIH—$9 billion above the enacted FY21 level—of which $6.5 billion is slated for the proposed Advanced Research Projects Agency for Health. While the $9 billion investment, if approved by Congress, would amount to the largest raise in the history of NIH, $2.5 billion of that TRUSELTIQ RECEIVES FDA ACCELERATED APPROVAL FOR METASTATIC Truseltiq (Infigratinib) a kinase inhibitor for adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 fusion or other rearrangement as detected by an FDA-approved test. Truseltiq is sponsored by BridgeBio Pharma/QED Therapeutics and Helsinn Group. FDA also approved FoundationOne CDx (Foundation PRECISION ONCOLOGY MUST EVOLVE TO ADDRESS HEALTH Every person facing a cancer diagnosis deserves access to the best possible tests and treatments for their disease. It’s really that simple. Even better—it’s entirely feasible. Biomarker-based cancer therapies are the cornerstone of precision oncology and hold promise for expanding access to the most effective treatment options for every patient. With genomic profiling, we can AMERICAN RED CROSS AND AMERICAN CANCER SOCIETY COLLABORATE The American Red Cross and the American Cancer Society are collaborating to encourage people to donate blood for cancer treatment. According to the American Cancer Society, many patient visits and procedures were forced to delay or cancel early in the pandemic to reduce the risk of exposure to COVID-19. With procedures resuming, blood donations are BREAKING NEW GROUND: NATHANIEL BERLIN, PAUL MARKS, AND VAL Nathaniel Berlin on the Diagnostic Radiology Program Nathaniel Berlin, an experimental hematologist, joined NCI in 1956 as head of the Metabolism Service in the General Medicine Branch and held that position until 1966, when he became chief of NCI’s Metabolism Branch, a position he held until 1971. This interview was conducted by History Associates Incorporated HOME - THE CANCER LETTEROHIO STATE EXPANDS ASSISTANCE PROGRAM TO GIVE OUT PREVIOUSLY DISPENSED CANCER DRUGSCALENDARCANCER LETTER IMPACT FACTORCANCER LETTER SUBMIT May 14, 2021. May 07, 2021. Apr 30, 2021. View More. The Cancer Letter is an independent weekly news publication and the leading source for information on the issues that shape oncology.THE CANCER LETTER
All issues of The Cancer Letter, from inception in 1973 through the present, are available in our digital archives. SEARCH. ST. JUDE’S $11.5B, SIX-YEAR PLAN AIMS TO IMPROVE GLOBAL Small dreams have no power to move hearts, and in a new six-year strategic plan, St. Jude Children’s Research Hospital is thinking very big. What would it take to drastically increase cure rates for childhood cancer worldwide? St. Jude’s answer: $11.5 billion and an additional 1,400 jobs. To get a rough sense of scale, work BIDEN REQUESTS $6.5B TO FUND CANCER-FOCUSED ARPA-H, AN The FY21 RCRP program announcements and General Application Instructions for the FY21 Department of Defense Rare Cancers Research Program to support research of exceptional scientific merit in the area of rare cancers research the following award mechanisms are CHERNOBYL - THE CANCER LETTER Gale’s series of four essays is among The Cancer Letter ’s most read stories in 2019, and it has been quoted worldwide. We have just given the Russian news publication Kommersant Nauka permission to excerpt and translate Gale’s essays. To drill deeper into the Chernobyl story, you might want to look at Gale’s detailed accountof
“1001CUTS”—A GYN ONCOLOGIST EXAMINES THE TOLL OF SEXISM IN The documentary is being completed, and the trailer is available here.The goal is for the film to be released in early 2022. Temkin is raising funds for the production costs here. “When I thought about it, telling a story about the OR made the most sense, and the stories of women and their personal experiences as surgeons in the operating room seemed like the highest impact place to tell the CTCA LEAVES TULSA AND PHILADELPHIA; TULSA MOVE COMES AMID “CTCA will continue investing in key markets that will build on more than 30 years of patient-centered, high-quality care.” Philadelphia is a tough market, where CTCA had to compete with three NCI-designated institutions—two of them Comprehensive Cancer Centers—located in the city limits as well as multiple high-quality health systems in theregion.
ISSUE 18 - THE CANCER LETTER Prominent GI oncologist Axel Grothey was forced out of Mayo Clinic for unethical sexual relationships with women he mentored Three reprimands later, he retains leadership—and mentorship—positions MACE ROTHENBERG STEPS DOWN AS PFIZER CMO, REPLACED BY Mace Rothenberg has stepped down as chief medical officer at Pfizer. His successor is Aida Habtezion, a Stanford researcher whose work is focused on leukocyte recruitment and immune responses in diseases affecting the digestive organs. Rothenberg, who served as the Pfizer CMO for two years, announced his move on social media Jan. 4. “Todayis
HOW REAL WORLD EVIDENCE WAS USED TO SUPPORT APPROVAL OF Pfizer provided the results of an analysis of real world data (RWD) from electronic health records (EHRs) as additional supportive data to characterize the use of Ibrance in combination with endocrine therapy (aromatase inhibitor or fulvestrant) in male patients with breast cancer based on observed tumor responses in this rare subset of patients with breast cancer. HOME - THE CANCER LETTEROHIO STATE EXPANDS ASSISTANCE PROGRAM TO GIVE OUT PREVIOUSLY DISPENSED CANCER DRUGSCALENDARCANCER LETTER IMPACT FACTORCANCER LETTER SUBMIT May 14, 2021. May 07, 2021. Apr 30, 2021. View More. The Cancer Letter is an independent weekly news publication and the leading source for information on the issues that shape oncology.THE CANCER LETTER
All issues of The Cancer Letter, from inception in 1973 through the present, are available in our digital archives. SEARCH. ST. JUDE’S $11.5B, SIX-YEAR PLAN AIMS TO IMPROVE GLOBAL Small dreams have no power to move hearts, and in a new six-year strategic plan, St. Jude Children’s Research Hospital is thinking very big. What would it take to drastically increase cure rates for childhood cancer worldwide? St. Jude’s answer: $11.5 billion and an additional 1,400 jobs. To get a rough sense of scale, work BIDEN REQUESTS $6.5B TO FUND CANCER-FOCUSED ARPA-H, AN The FY21 RCRP program announcements and General Application Instructions for the FY21 Department of Defense Rare Cancers Research Program to support research of exceptional scientific merit in the area of rare cancers research the following award mechanisms are CHERNOBYL - THE CANCER LETTER Gale’s series of four essays is among The Cancer Letter ’s most read stories in 2019, and it has been quoted worldwide. We have just given the Russian news publication Kommersant Nauka permission to excerpt and translate Gale’s essays. To drill deeper into the Chernobyl story, you might want to look at Gale’s detailed accountof
“1001CUTS”—A GYN ONCOLOGIST EXAMINES THE TOLL OF SEXISM IN The documentary is being completed, and the trailer is available here.The goal is for the film to be released in early 2022. Temkin is raising funds for the production costs here. “When I thought about it, telling a story about the OR made the most sense, and the stories of women and their personal experiences as surgeons in the operating room seemed like the highest impact place to tell the CTCA LEAVES TULSA AND PHILADELPHIA; TULSA MOVE COMES AMID “CTCA will continue investing in key markets that will build on more than 30 years of patient-centered, high-quality care.” Philadelphia is a tough market, where CTCA had to compete with three NCI-designated institutions—two of them Comprehensive Cancer Centers—located in the city limits as well as multiple high-quality health systems in theregion.
ISSUE 18 - THE CANCER LETTER Prominent GI oncologist Axel Grothey was forced out of Mayo Clinic for unethical sexual relationships with women he mentored Three reprimands later, he retains leadership—and mentorship—positions MACE ROTHENBERG STEPS DOWN AS PFIZER CMO, REPLACED BY Mace Rothenberg has stepped down as chief medical officer at Pfizer. His successor is Aida Habtezion, a Stanford researcher whose work is focused on leukocyte recruitment and immune responses in diseases affecting the digestive organs. Rothenberg, who served as the Pfizer CMO for two years, announced his move on social media Jan. 4. “Todayis
HOW REAL WORLD EVIDENCE WAS USED TO SUPPORT APPROVAL OF Pfizer provided the results of an analysis of real world data (RWD) from electronic health records (EHRs) as additional supportive data to characterize the use of Ibrance in combination with endocrine therapy (aromatase inhibitor or fulvestrant) in male patients with breast cancer based on observed tumor responses in this rare subset of patients with breast cancer. NCI TRIALS FOR JUNE 2021 The National Cancer Institute approved the following clinical research studies last month. For further information, contact the principal investigator listed. Phase I – 10347 A Phase I Study with an Expansion Cohort of Duvelisib and Nivolumab in Mycosis Fungoides (MF) and SÈzary Syndrome (SS) Yale University Cancer Center LAO Mehta-Shah, Neha (314) 747-7402 Phase AS AXEL GROTHEY BECOMES AN EMBLEM OF SEXUAL MISCONDUCT IN Inappropriate sexual relationships of the sort Axel Grothey engaged in at Mayo Clinic may be all too common. The Grothey case is unique, because it has slipped out from under the cloak of confidentiality, making Grothey into a symbol of sexual misconduct, including abuse of power in the relationship between mentor and mentee. The Cancer LUMAKRAS RECEIVES FDA ACCELERATED APPROVAL FOR KRAS G12C FDA has granted accelerated approval to Lumakras (sotorasib) a RAS GTPase family inhibitor, for adult patients with KRAS G12C ‑mutated locally advanced or metastatic non-small cell lung cancer, as determined by an FDA ‑approved test, who have received at least one prior systemic therapy. Lumakras is sponsored by Amgen. FDA also approved the Qiagen therascreen TRUSELTIQ RECEIVES FDA ACCELERATED APPROVAL FOR METASTATIC Truseltiq (Infigratinib) a kinase inhibitor for adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 fusion or other rearrangement as detected by an FDA-approved test. Truseltiq is sponsored by BridgeBio Pharma/QED Therapeutics and Helsinn Group. FDA also approved FoundationOne CDx (Foundation AMERICAN RED CROSS AND AMERICAN CANCER SOCIETY COLLABORATE The American Red Cross and the American Cancer Society are collaborating to encourage people to donate blood for cancer treatment. According to the American Cancer Society, many patient visits and procedures were forced to delay or cancel early in the pandemic to reduce the risk of exposure to COVID-19. With procedures resuming, blood donations are SENATE LEADERS SHOW BIPARTISAN SUPPORT FOR BIDEN’S FY22 President Joe Biden is requesting $52 billion in FY2022 for NIH—$9 billion above the enacted FY21 level—of which $6.5 billion is slated for the proposed Advanced Research Projects Agency for Health. While the $9 billion investment, if approved by Congress, would amount to the largest raise in the history of NIH, $2.5 billion of that “1001CUTS”—A GYN ONCOLOGIST EXAMINES THE TOLL OF SEXISM IN The documentary is being completed, and the trailer is available here.The goal is for the film to be released in early 2022. Temkin is raising funds for the production costs here. “When I thought about it, telling a story about the OR made the most sense, and the stories of women and their personal experiences as surgeons in the operating room seemed like the highest impact place to tell the PRECISION ONCOLOGY MUST EVOLVE TO ADDRESS HEALTH Every person facing a cancer diagnosis deserves access to the best possible tests and treatments for their disease. It’s really that simple. Even better—it’s entirely feasible. Biomarker-based cancer therapies are the cornerstone of precision oncology and hold promise for expanding access to the most effective treatment options for every patient. With genomic profiling, we can BREAKING NEW GROUND: NATHANIEL BERLIN, PAUL MARKS, AND VAL Nathaniel Berlin on the Diagnostic Radiology Program Nathaniel Berlin, an experimental hematologist, joined NCI in 1956 as head of the Metabolism Service in the General Medicine Branch and held that position until 1966, when he became chief of NCI’s Metabolism Branch, a position he held until 1971. This interview was conducted by History Associates Incorporated JOHN GLICK TO RETIRE FROM PENN MEDICINE John H. Glick, president of the Abramson Family Cancer Research Institute at Penn Medicine, professor of medicine, and the Madlyn & Leonard Abramson Professor of Clinical Oncology, will retire at the end of the academic year and assume emeritus status. Glick joined the Penn faculty in 1974 as the Ann B. Young Assistant Professor, afterToggle navigation
* Home
* IP Login
* Individual Login
* Subscribe
* Mailing List
* About TCL
* Past Issues
* Advertise
* Contact Us
* Calendar
* Journalism Awards
* Institutional Subscriptions* FAQS
* Copyright
Search
* Calendar
* Journalism Awards
* Institutional Subscriptions* FAQS
* Copyright
Search
Issue 45 - Dec. 4, 2020*
FEDERATE THE DATA: NCI PRODUCES MASTER PLAN FOR THE CHILDHOOD CANCERDATA INITIATIVE
NCI is using a hub-and-spoke structure to engineer an ambitious data federation for pediatric cancers—which, if done right, is anticipated to become the gold standard for a new generation of comprehensive cancer databases.*
_NCI DIRECTOR’S REPORT_ SHARPLESS: “THIS IS ONE OF THE MOST UNCERTAIN BUDGET ENVIRONMENTS THAT I THINK THE NCI HAS EVER EXPERIENCED.” NCI has joined a nationwide initiative to increase the number of underrepresented minority faculty at NIH-funded cancer hospitals.*
CANCER GROUPS SAY TRUMP ADMINISTRATION’S DRUG PRICING RULE WILL LIKELY HARM PATIENTS On the way out, the Trump administration has finalized a rule that uses international reference prices to lower Medicare Part B prices.*
_IN BRIEF_
* GRAIL AND UK GOVERNMENT PLAN TO MAKE GALLERI MULTI-CANCER EARLY DETECTION BLOOD TEST AVAILABLE * Raymond Bergan named deputy director at Fred & Pamela BuffettCancer Center
* Ramsay Camp named chief of surgical oncology at Baylor College ofMedicine
* IU’s Harikrishna Nakshatri receives $1.3 million to improve breast cancer treatment for Black women * FDA and AACR collaborate on Project Livin’ Label * Ohio State creates Clara D. Bloomfield Center for leukemia outcomesresearch
*
*
_TRIALS & TRIBULATIONS_ HOW AI UNCOVERS “INVISIBLE” SOCIOECONOMIC RISK FACTORS TO IMPROVECANCER CARE
During my 30-year career in health care, I’ve worked with hundreds of community oncology practices. Most oncologists I’ve worked with have, for quite some time, intuitively understood that social determinants of health (SDOH) can significantly impact patientoutcomes.
*
_CLINICAL ROUNDUP_
* UVA RESEARCHERS IDENTIFY GENE RESPONSIBLE FOR METASTASIS OF TNBC * City of Hope initiates phase I study to test its first SARS-CoV-2 investigational vaccine*
_DRUGS & TARGETS_
* DANYELZA RECEIVES FDA APPROVAL FOR TREATMENT OF NEUROBLASTOMA * Gavreto receives FDA approval for RET-altered thyroid cancers * FDA approves first PSMA-targeted PET imaging drug for in prostatecancer
* European Commission approves Opdivo as second-line treatment for unresectable advanced, recurrent or metastatic ESCC * EMA validates tepotinib application for treatment of advanced NSCLC with METex14 skipping alterations*
_NCI TRIALS_
NCI TRIALS FOR DECEMBER 2020 The National Cancer Institute approved the following clinical researchstudies last month.
Issue 44 - Nov. 20, 2020*
_CONVERSATION WITH THE CANCER LETTER_ ASCO’S NEW CMO JULIE R. GRALOW WILL FOCUS ON EQUITY, ADVOCACY, ANDGLOBAL HEALTH
Julie R. Gralow, an expert in breast cancer, clinical trials and global health, was named chief medical officer of the American Society of Clinical Oncology.*
CANCER HOSPITALS STAY OPEN AS COVID-19 CASES SKYROCKET The United States faces the worst-yet surge of COVID-19, but cancer hospitals have learned to adapt to the pandemic, opting to continue cancer services at an unchanged pace.*
_NEWS ANALYSIS_
TRUMP ET AL. ARE WRONG: BIDEN CANCER INITIATIVE IS NOT TO BE CONFUSED WITH THE BEAU BIDEN CANCER MOONSHOT On Nov. 15, shortly after midnight, President Donald J. Trump tweeted a link to a_ New York Post_ headline: “Tax filings reveal Biden cancer charity spent millions on salaries,zero on research”
Waking up later that morning, Fox News host Laura Ingraham and former Trump campaign manager Corey Lewandowski, gleefully lent their voices to the now-familiar cacophony of disinformation. A day later, Fox News host Sean Hannity joined their chorus.*
_LETTER TO THE EDITOR_ AACI: PRESIDENT-ELECT BIDEN HAS PROVEN HIS UNYIELDING COMMITMENT TODEFEATING CANCER
In a year of monumental health care and operational challenges for cancer centers, the Association of American Cancer Institutes marks with enthusiasm the electoral victory of a presidential candidate who has proven his unyielding commitment to defeating cancer.*
_IN BRIEF_
* HANNAH HAZARD-JENKINS NAMED DIRECTOR OF WVU CANCER INSTITUTE * Edward S. Kim named physician-in-chief of City of Hope OrangeCounty
* Julia H. Rowland and Tom Smith receive NCCS Ellen L. Stovall Award * Jedd Wolchok receives Hearst Foundation Grant * CPRIT awards $26 million in new recruitment grants * New AMA policy recognizes racism as a public health threat * ASTRO: Radiation oncologists urge Congress to advance bills that protect patient access to cancer care during the pandemic*
*
_CLINICAL ROUNDUP_
* IN VITRO FERTILIZATION DOES NOT INCREASE THE RISK OF OVARIAN CANCER * UCLA researchers find patients with lung cancer most likely to respond to immunotherapy * AI can pick the best candidates for skin cancer treatment * Phase III trial shows decrease of chemotherapy-induced neutropenia * Neratinib in HER2-positive HR-negative early stage breast cancer shows DFS benefit vs. placebo*
_DRUGS & TARGETS_
* KEYTRUDA RECEIVES ACCELERATED APPROVAL FROM FDA FOR LOCALLY RECURRENT, UNRESECTABLE OR METASTATIC TNBC * FDA issues draft guidance to provide important considerations in cross labeling of oncology drugs * CDER and CBER to increase Emergency Use Authorization transparency * Agendia and Paige collaborate on breast cancer research Issue 43 - Nov. 13, 2020*
_NEWS ANALYSIS_
JOE BIDEN HAS AN UNPARALLELED GRASP OF THE SCIENCE AND POLITICS OFCANCER
For the first time in U.S. history, the White House will soon be occupied by a president who has demonstrated a deep understanding ofcancer research.
*
_GUEST EDITORIAL_
A BIDEN-HARRIS ADMINISTRATION WILL HELP SUSTAIN OUR MOMENTUM IN THE FIGHT AGAINST CANCER The recent historic election of President-elect Joe Biden and Vice President-elect Kamala Harris provides an exciting opportunity for the cancer research and medical science communities during the next four years to dramatically improve the health of our nation and the world.*
_AN APPRECIATION_
DAVID A. AHLQUIST, PIONEER OF CANCER SCREENING, DIES AT 69 With unwavering positivity and unquenchable curiosity, David A. Ahlquist, MD, turned complex challenges into addressable opportunities, and audacious ideas into achievable realities.*
_IN BRIEF_
* ABRAHAM CHACHOUA NAMED DIRECTOR OF PERLMUTTER CANCER CENTER’SLUNG CANCER CENTER
* CWRU and UH Researchers receive $5 million from NCI to investigate relationships between HIV and lung cancer in East Africa * John Turchi receives $2.9 million from NCI to improve effectiveness of lung cancer radiation therapy * SWOG and The Hope Foundation award two grants designed to give military veterans better access to cancer clinical trials * The US Oncology Network enrolls 100,000th patient in the OncologyCare Model
*
*
_TRIALS & TRIBULATIONS_ #BCSM: BREAST CANCER SOCIAL MEDIA HASHTAG GIVES VOICE TO A COMMUNITY When they decided to launch a weekly breast cancer chat on Twitter, all breast cancer survivors and advocates Alicia Staley and Jody Schoger had was a hashtag and a dream.*
_CLINICAL ROUNDUP_
* KEYTRUDA + LENVIMA MEET PFS PRIMARY ENDPOINT IN ADVANCED RCC * KEYNOTE-695 study: Tavo + Keytruda demonstrate 30% ORR in anti-PD-1 checkpoint refractory metastatic melanoma * State-level lung cancer screening rates are not aligned with lung cancer burden in the U.S. * Diagnostic imaging may increase risk of testicular cancer * JNCCN study evaluates cost-effectiveness of olaparib for metastaticpancreatic cancer
* Research detects hormone-upregulated lncRNA within the lymphocyte-specific protein tyrosine kinase discovered in prostatecancer
*
_DRUGS & TARGETS_
* FDA APPROVES LIQUID BIOPSY NGS COMPANION DIAGNOSTIC TEST FOR MULTIPLE CANCERS AND BIOMARKERS * FDA issues guidance to enhance diversity in clinical trials, encourage inclusivity in medical product development * European Commission approves Opdivo + Yervoy with two cycles of chemotherapy for first-line treatment of metastatic NSCLC1 2 3
4
5
6
7
8
9
10
11
… 115
>
* About TCL
* Advertise
* Institutional Subscriptions* Privacy Policy
* Terms of Service
* Contact Us
The Cancer Letter Inc.PO Box 9905
Washington
DC 20016
Tel: 202-362-1809
Fax: 202-379-1787
Twitter:
@TheCancerLetter
Facebook:
/TheCancerLetter
Copyright (c) 2020 The Cancer Letter Inc. BY CONTINUING TO USE OUR SITE, YOU AGREE TO OUR TERMS OF SERVICEAND PRIVACY POLICY
. YOU CAN LEARN MORE ABOUT HOW WE USE COOKIES BY REVIEWING OUR PRIVACY POLICY.
Details
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0